Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Rheumatology (Oxford, England)|June 8, 2014
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentErnest Choy, Kandeepan Ganeshalingam, Anne Grete Semb, et al.Drug Safety|January 11, 2018
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature ReviewMichael Nurmohamed, Ernest Choy, Sadiq Lula, et al.RMD Open|November 5, 2015
Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritisMichael Nurmohamed, Yanjun Bao, James Signorovitch, et al.Clinical Rheumatology|April 13, 2011
Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activityIzhar C van Eijk, Erik H Serné, Ben A C Dijkmans, et al.Nutrients|December 11, 2019
Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic ReviewDaisy Vedder, Wendy Walrabenstein, Maaike Heslinga, et al.Journal of Clinical Immunology|May 25, 2012
IgG4 production against adalimumab during long term treatment of RA patientsPauline A van Schouwenburg, Charlotte L Krieckaert, Michael Nurmohamed, et al.International Journal of Clinical Practice|August 19, 2010
The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be betterM J L Peters, A E Voskuyl, N Sattar, et al.Annals of the Rheumatic Diseases|May 26, 2010
Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA studyA Jamnitski, I M Visman, M J L Peters, et al.European Journal of Internal Medicine|March 31, 2023
Older patients with nonspecific complaints at the Emergency Department are at risk of adverse health outcomesC S van Dam, M J L Peters, E O Hoogendijk, et al.European Journal of Endocrinology|February 27, 2007
Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritisI C van Eijk, M J L Peters, M T Nurmohamed, et al.Pageof 5